2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Outstanding mix of clinical abstracts, including clinical trials, retrospective analysis, and molecular observations in myelofibrosis, polycythemia vera, essential thrombocythemia and other myeloid neoplasms
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2047 Real-world validation of survival benefit associated with interferon alfa use in myelofibrosis

Katie Erdos, BA, Neville Lee Jr, BSc, BA2, Joseph Scandura, MD, PhD3, Ghaith Abu-Zeinah I, MD4
1 Weill Cornell Medicine, New York, New York, United States
2 Weill Cornell Medicine, New York, New York, United States
3 Weill Cornell Medicine, New York, New York, United States
4 Weill Cornell Medicine, New York, New York, United States

Background: Interferon alfa (IFN) is a disease-modifying therapy for myeloproliferative neoplasms (MPN) shown to target malignant stem cells and improve event-free survival (EFS). Whether IFN improves EFS or overall survival (OS) in primary myelofibrosis (PMF) is an important question in the MPN field that merits investigation. A recent phase 2 trial showed ropeginterferon alfa-2b is well-tolerated and induces significant clinical, hematologic, and molecular responses in prefibrotic and lower-risk overt myelofibrosis (pre/LR-MF) (Gill et al. Blood Advances, 2026), and the randomized phase 3 HOPE-PMF trial is ongoing (Abu-Zeinah et al. Ann Hematol, 2024). Simultaneously, we reported a single-center novel finding that IFN in pre/LR-MF was associated with improved OS (Erdos et al. Blood, 2025). To validate this finding in a larger multi-center real-world cohort, we leveraged the TriNetX electronic health record database for a comparative analysis of outcomes associated with IFN in patients (pts) with MF.

Methods: Pts in the TriNetX database with an International Classification of Diseases (ICD) code for MF, age ≥18 years (yrs), were included. Treatment exposure was determined via SNOMED codes, with pts that received ≥1 yr of peginterferon alfa-2a or ropeginterferon alfa-2b assigned to the IFN group. Controls (NoIFN) were pts with no or <1 yr of IFN exposure but were required to have ≥1 yr of follow-up to prevent immortal time bias. The groups were propensity-matched on the Dynamic International Prognostic Scoring System Plus (DIPSS+) variables of age, hemoglobin, white blood count, platelets, and peripheral blasts at diagnosis (dx) or IFN initiation (Gangat et al. J Clin Oncol, 2011). Summary statistics were used to compare demographics and clinical variables. Leukemic progression was annotated using ICD codes. RBC transfusions were extracted based on ICD and Current Procedural Terminology codes. Progression was defined as transfusion requirement or crossing of a DIPSS+ lab into the higher-risk category, confirmed on ≥2 consecutive values. OS, leukemia-free survival (LFS), and progression-free survival (PFS) were assessed using the Kaplan-Meier method and compared using log-rank test. Cox proportional-hazards models were used for univariable and multivariable analysis (MVA) of mortality, leukemia risk, and progression risk.

Results: We identified 94 pts with MF that were treated with IFN for ≥1 yr, who were matched 1:12 to 1128 NoIFN pts. Median age at dx was 63 yrs in the IFN cohort vs 61 in the NoIFN cohort. The IFN cohort was comprised of more females (63% vs 47% NoIFN, p<0.01) but was otherwise similar to the NoIFN in race/ethnicity, baseline labs, and DIPSS+ risk (46% vs 48% low, 46% vs 48% intermediate-1, and 9% vs 9% intermediate-2 risk by age and labs for IFN vs NoIFN, respectively). Median follow-up duration was similar (3.3 yrs [range 0.4-9.8] IFN vs 4.4 yrs [range 1-16] NoIFN, p=0.08). Median time from dx to IFN initiation was 0.1 yrs; median IFN duration was 2.7 yrs (range 1.0-11 yrs). Among NoIFN pts, 30% were on observation only; the remainder received one or more cytoreductive therapies, including ruxolitinib (46%) and hydroxyurea (44%). Median OS was significantly longer in the IFN group, with 5-yr OS rate of 99% vs 82% in the IFN vs NoIFN groups respectively, (p<0.01, median not reached in the IFN group; 12 yrs in NoIFN). MVA confirmed that IFN duration (per yr) was associated with a mortality risk reduction, independent of age, sex, or DIPSS+ factors (HR 0.78, CI 0.62-0.98, p<0.03). LFS was similar between groups: 5-yr LFS rate was 91% in both, p=0.5. PFS was significantly longer in the IFN group, with 5-yr PFS rate of 80% IFN vs 69% NoIFN, p<0.01. IFN duration was independently associated with longer PFS in MVA with age, sex, and DIPSS+ lab parameters as covariates (HR 0.89, CI 0.82-0.96, p<0.01).

Conclusion: In our retrospective, multi-institutional analysis of 1222 pts with MF, IFN was associated with significantly lower mortality risk and prolonged PFS, independent of age, sex, and DIPSS+ lab criteria. These findings validate our single-center observation of an OS benefit with IFN in a global, real-world population. Together with emerging prospective data supporting the efficacy of IFN in the pre/LR-MF population, these results strengthen the rationale for long-term IFN use in select pts with MF. Further randomized, prospective evaluation is key to understanding the effects of IFN on outcomes in MF.

Katie Erdos, BA: No relevant conflicts of interest to declare.